BHC

AI Memo

Bausch Health Companies

As of 2026-09-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 results and FY2026 guidance raise • 2026-07-29

Base target: $8 / p=50% prob

Biggest risk

The key downside is whether second-half gross-to-net changes, Aplenzin loss of exclusivity, and Medicaid/former 340B erosion offset the strong Q2 trajectory. Recent insider sales add sentiment risk but are not evidence of operating deterioration [#PR-EARNINGS-2026-08-21] [#SEC-FORM4-2026-08-20].

Invalidation

Break below $5 or thesis failure.

What would change my mind?

The Q2 print showed strong reported and organic growth, higher adjusted EBITDA, substantial operating cash flow, and a full-year guidance raise. Continued execution could support further deleveraging and investment flexibility [#SEC-8K-2026-07-29].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-02

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Cash-flow conversion and debt-reduction follow-through
Second-half commercial and gross-to-net pressure
The Q2 print showed strong reported and organic growth, higher adjusted EBITDA, substantial operating cash flow, and a full-year guidance raise.

BearKey bullets

Aplenzin loss of exclusivity may pressure commercial performance.
Execution risk in converting strong operating cash flow into sustained net-debt reduction.
Recent open-market insider sales could weigh on sentiment, though they do not establish an operating thesis [#SEC-FORM4-2026-08-20].

WatchKey bullets

Q2 results and FY2026 guidance raise

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $8 (p=50%)

Target spread vs base: +9% / -31%

Scenario probabilities

Bull Target: $8 (p=25%)Base Target: $8 (p=50%)Bear Target: $5 (p=25%)

Commentary

News tone is moderately positive after the Q2 results and guidance raise. Third-party coverage also described improving earnings estimates, but exact post-release price reaction, analyst target revisions, options skew, short interest, employee sentiment, and social coverage are unavailable. The evidence supports cautious bullish monitoring rather than high-conviction accumulation.

As of 2026-09-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Cash-flow conversion and debt-reduction follow-through
Second-half commercial and gross-to-net pressure

Scenarios

Bull Target (Scenario probability)

$8 / p=25% prob

Base Target (Scenario probability)

$8 / p=50% prob

Bear Target (Scenario probability)

$5 / p=25% prob

Analysis 2026-09-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.65

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-07-29
Q2 results and FY2026 guidance raise
Bausch reported Q2 revenue of $2.85 billion, adjusted EPS of $1.26, adjusted EBITDA of $1.075 billion, and raised full-year 2026 revenue, adjusted EBITDA, and adjusted cash-flow guidance [#SEC-8K-2026-07-29].
Prob 95.00% • Move 8.00% • Priced-in 85.00%

Short-term Catalysts

Next few weeks

Cash-flow conversion and debt-reduction follow-through
2026-12-01
Q2 operating cash flow was $517 million and adjusted cash flow from operations was $471 million; continued cash generation and net-debt reduction could improve financial flexibility [#SEC-8K-2026-07-29].
Prob 65% • Move 7% • Priced-in 45%
Second-half commercial and gross-to-net pressure
2026-12-01
Third-party earnings coverage cited potential second-half pressure from gross-to-net accrual changes, Aplenzin loss of exclusivity, and erosion in Medicaid and former 340B revenue [#PR-EARNINGS-2026-08-21].
Prob 70% • Move -12% • Priced-in 35%

Long-term Catalysts

Months to a year

No long-term catalysts

Risks

Aplenzin loss of exclusivity may pressure commercial performance.
Execution risk in converting strong operating cash flow into sustained net-debt reduction.
Recent open-market insider sales could weigh on sentiment, though they do not establish an operating thesis [#SEC-FORM4-2026-08-20].
Second-half gross-to-net accrual pressure and erosion in Medicaid and former 340B revenue.

Peers

Symbol	Summary
AMGN	Large-cap biopharma reference, but materially different scale, balance sheet, portfolio, and leverage profile.
GILD	Large-cap biopharma reference with limited direct comparability to BHC's diversified commercial operations and leverage.
COAG	Same-sector, similar-market-cap screening candidate; direct product, pipeline, and leverage comparability is not established.
PHVS	Same-sector, similar-market-cap screening candidate; direct comparability to BHC's diversified portfolio is limited.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-02

Loading AI feed…

Symbol

Summary

AMGN

Large-cap biopharma reference, but materially different scale, balance sheet, portfolio, and leverage profile.

GILD

Large-cap biopharma reference with limited direct comparability to BHC's diversified commercial operations and leverage.

COAG

Same-sector, similar-market-cap screening candidate; direct product, pipeline, and leverage comparability is not established.

PHVS

Same-sector, similar-market-cap screening candidate; direct comparability to BHC's diversified portfolio is limited.